Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
3D-CRT in dogs with massive hepatocellular carcinoma
Hepatic tumors often are either too big for surgical resection or the owner decline this operation. This recently online published study evaluates the activity and tolerability of three-dimensional conformal radiation therapy (3D-CRT) in six dogs with massive hepatocellular carcinoma.

Six dogs with massive hepatocellular carcinoma that were ineligible for surgical resection or with owners who declined surgical resection, and underwent 3D-CRT were retrospectively reviewed.

6 to 10 Gy per fraction was prescribed at isocentre of planning target volume to a total dose of 18 to 42 Gy with 1 to 2 fractions per week for a total of 3 to 7 fractions.

Follow-up examinations included physical examination, contrast-enhanced CT scan and blood analysis (complete blood count, electrolytes and serum biochemical panel).

The median follow-up time after 3D-CRT was 534 (range, 281 to 1057) days.

An objective response was observed in five of six cases.

Radiation-induced liver disease developed in one dog but was asymptomatic and reversible.

Toxicity was not noted in any other dog.

3D-CRT appears to be a viable treatment option for dogs with inoperable massive hepatocellular carcinoma.


Source: Mori, T., Ito, Y., Kawabe, M., Iwasaki, R., Sakai, H., Murakami, M. and Maruo, K. (2015), Three-dimensional conformal radiation therapy for inoperable massive hepatocellular carcinoma in six dogs. Journal of Small Animal Practice, 56: 441–445. doi: 10.1111/jsap.12352




Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Prognostic factors in cats with HCMmembers
Left atrial (LA) enlargement, congestive heart failure (CHF), and aortic thromboembolism (ATE) are associated with decreased survival in cats with hypertrophic cardiomyopathy (HCM), but the prognostic value of echocardiographic variables has not been well characterized. Do LA echocardiographic variables and assessment of left ventricular (LV) diastolic and systolic function have prognostic value in cats with HCM?

  • Effect of Heart Rate on Survival in Dogs with Atrial Fibrillation
  • Ureteral Papilla Implantation in Cats Undergoing Renal Transplantationmembers
  • Storage lesion in canine packed erythrocytesmembers
  • Drug-induced infiltrative lung disease with cytarabine and prednisonemembers
  • Laparoscopic-assisted Gastropexy and the Gastrointestinal Transit Time in Dogsmembers
  • Transpalpebral ultrasonographic evaluation and measurement of the optic nerve members
  • Squamous cell carcinoma mimicking orbital myofibroblastic sarcomamembers
  • Unusual case of feline acute corneal hydropsmembers
  • Shock index in identifying acute blood loss in healthy dogsmembers
  • Correlation of direct in-house cerebrospinal fluid cytology with commercial pathology results members
  • 3 Serological Tests for Early Detection Of Leptospira-specific Antibodies members
  • Patient-specific facemask to facilitate brain biopsymembers


  • [ Home ] [ About ] [ Contact / Request ][ Disclaimer ]

    Copyright © 2001-2016 VetContact GmbH
    All rights reserved